
Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.
Supplements and Featured Publications
over 24 years ago
Statin Pharmacology May Have Important Clinical Implicationsover 24 years ago
Role of hs-CRP in Cardiovascular Risk Predictionover 24 years ago
Changes in ATP III focus on diabetes and the metabolic syndromeover 24 years ago
Aggressive Lipid Reduction Provides Additional Clinical Benefit


